Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives

Overview

Journal Nutrients

Date 2021 Jun 2

PMID 34063372

Citations 8

Authors

Marcello Dallio

Mario Romeo

Antonietta Gerarda Gravina

Mario Masarone

Tiziana Larussa

Ludovico Abenavoli

Marcello Persico

Carmelina Loguercio

Alessandro Federico

Affiliations

Soon will be listed here.

Abstract

Metabolic- (dysfunction) associated fatty liver disease (MAFLD) represents the predominant hepatopathy and one of the most important systemic, metabolic-related disorders all over the world associated with severe medical and socio-economic repercussions due to its growing prevalence, clinical course (steatohepatitis and/or hepatocellular-carcinoma), and related extra-hepatic comorbidities. To date, no specific medications for the treatment of this condition exist, and the most valid recommendation for patients remains lifestyle change. MAFLD has been associated with metabolic syndrome; its development and progression are widely influenced by the interplay between genetic, environmental, and nutritional factors. Nutrigenetics and nutrigenomics findings suggest nutrition's capability, by acting on the individual genetic background and modifying the specific epigenetic expression as well, to influence patients' clinical outcome. Besides, immunity response is emerging as pivotal in this multifactorial scenario, suggesting the interaction between diet, genetics, and immunity as another tangled network that needs to be explored. The present review describes the genetic background contribution to MAFLD onset and worsening, its possibility to be influenced by nutritional habits, and the interplay between nutrients and immunity as one of the most promising research fields of the future in this context.

Citing Articles

Dietary and health risk behaviors for metabolic diseases in different age groups: a cross-sectional study in Chongqing, China.

Qin H, Zhao M, Wu T, Zhu S, Qiao Y, Lei X BMC Public Health. 2025; 25(1):683.

PMID: 39972332 PMC: 11837718. DOI: 10.1186/s12889-025-21898-y.

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?.

Romeo M, Dallio M, Napolitano C, Basile C, Di Nardo F, Vaia P Diagnostics (Basel). 2025; 15(3).

PMID: 39941182 PMC: 11817573. DOI: 10.3390/diagnostics15030252.

The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition.

Dallio M, Sangineto M, Romeo M, Cipullo M, Coppola A, Mammone S Nutr Diabetes. 2024; 14(1):33.

PMID: 38802382 PMC: 11130147. DOI: 10.1038/s41387-024-00294-2.

Ketogenic therapy towards precision medicine for brain diseases.

Liu Y, Fan L, Yang H, Wang D, Liu R, Shan T Front Nutr. 2024; 11:1266690.

PMID: 38450235 PMC: 10915067. DOI: 10.3389/fnut.2024.1266690.

Association of food intake with a risk of metabolic dysfunction-associated fatty liver disease: a cross-sectional study.

Huang X, Peng H, Huang J, Yu R, Hu Z, Peng X Gastroenterol Rep (Oxf). 2023; 11:goad054.

PMID: 37705510 PMC: 10495696. DOI: 10.1093/gastro/goad054.

References

Shahidi F, Ambigaipalan P . Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. Annu Rev Food Sci Technol. 2018; 9:345-381. DOI: 10.1146/annurev-food-111317-095850. View

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Gurav A, Sivaprakasam S, Bhutia Y, Boettger T, Singh N, Ganapathy V . Slc5a8, a Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions. Biochem J. 2015; 469(2):267-78. PMC: 4943859. DOI: 10.1042/BJ20150242. View

Simopoulos A . An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016; 8(3):128. PMC: 4808858. DOI: 10.3390/nu8030128. View

Purushotham A, Schug T, Xu Q, Surapureddi S, Guo X, Li X . Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-38. PMC: 2668535. DOI: 10.1016/j.cmet.2009.02.006. View

de Mello V, Sehgal R, Mannisto V, Klavus A, Nilsson E, Perfilyev A . Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids. Liver Int. 2020; 41(4):754-763. PMC: 8048463. DOI: 10.1111/liv.14743. View

Liu X, Pan Q, Zhang R, Shen F, Yan S, Sun C . Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016; 22(44):9844-9852. PMC: 5124990. DOI: 10.3748/wjg.v22.i44.9844. View

Dongiovanni P, Crudele A, Panera N, Romito I, Meroni M, De Stefanis C . β-Klotho gene variation is associated with liver damage in children with NAFLD. J Hepatol. 2019; 72(3):411-419. DOI: 10.1016/j.jhep.2019.10.011. View

Erhartova D, Cahova M, Dankova H, Heczkova M, Mikova I, Sticova E . Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation. PLoS One. 2019; 14(11):e0224820. PMC: 6839850. DOI: 10.1371/journal.pone.0224820. View

10.

Van Name M, Savoye M, Chick J, Galuppo B, Feldstein A, Pierpont B . A Low ω-6 to ω-3 PUFA Ratio (n-6:n-3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. J Nutr. 2020; 150(9):2314-2321. PMC: 7467848. DOI: 10.1093/jn/nxaa183. View

11.

Liu Y, Reeves H, Burt A, Tiniakos D, McPherson S, Leathart J . TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:4309. PMC: 4279183. DOI: 10.1038/ncomms5309. View

12.

Kim M, Kang S, Park J, Yanagisawa M, Kim C . Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology. 2013; 145(2):396-406.e1-10. DOI: 10.1053/j.gastro.2013.04.056. View

13.

Nastasi C, Candela M, Bonefeld C, Geisler C, Hansen M, Krejsgaard T . The effect of short-chain fatty acids on human monocyte-derived dendritic cells. Sci Rep. 2015; 5:16148. PMC: 4635422. DOI: 10.1038/srep16148. View

14.

Meroni M, Longo M, Rustichelli A, Dongiovanni P . Nutrition and Genetics in NAFLD: The Perfect Binomium. Int J Mol Sci. 2020; 21(8). PMC: 7215858. DOI: 10.3390/ijms21082986. View

15.

Dongiovanni P, Meroni M, Baselli G, Mancina R, Ruscica M, Longo M . gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res. 2019; 60(6):1144-1153. PMC: 6547640. DOI: 10.1194/jlr.P090449. View

16.

Lindenmeyer C, McCullough A . The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2017; 22(1):11-21. PMC: 6130315. DOI: 10.1016/j.cld.2017.08.003. View

17.

Franzago M, Fraticelli F, Nicolucci A, Celentano C, Liberati M, Stuppia L . Molecular Analysis of a Genetic Variants Panel Related to Nutrients and Metabolism: Association with Susceptibility to Gestational Diabetes and Cardiometabolic Risk in Affected Women. J Diabetes Res. 2017; 2017:4612623. PMC: 5241477. DOI: 10.1155/2017/4612623. View

18.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

19.

Lee A, Mavaddat N, Wilcox A, Cunningham A, Carver T, Hartley S . BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019; 21(8):1708-1718. PMC: 6687499. DOI: 10.1038/s41436-018-0406-9. View

20.

Monteiro C, Moubarac J, Cannon G, Ng S, Popkin B . Ultra-processed products are becoming dominant in the global food system. Obes Rev. 2013; 14 Suppl 2:21-8. DOI: 10.1111/obr.12107. View